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v.karani@reading.ac.ukAbstractBackground and objective: Given the role of uncoupling protein 2 (UCP2) in the accumulation of fat in the hepatocytes and in
the enhancement of protective mechanisms in acute ethanol intake, we hypothesised that UCP2 polymorphisms are likely to
cause liver disease through their interactions with obesity and alcohol intake. To test this hypothesis, we investigated the
interaction between tagging polymorphisms in the UCP2 gene (rs2306819, rs599277 and rs659366), alcohol intake and
obesity traits such as BMI and waist circumference (WC) on alanine aminotransferase (ALT) and gamma glutamyl transferase
(GGT) in a large meta-analysis of data sets from three populations (nZ20 242).
Design and methods: The study populations included the Northern Finland Birth Cohort 1966 (nZ4996), Netherlands Study
of Depression and Anxiety (nZ1883) and LifeLines Cohort Study (nZ13 363). Interactions between the polymorphisms and
obesity and alcohol intake on dichotomised ALT and GGT levels were assessed using logistic regression and the likelihood
ratio test.
Results: In the meta-analysis of the three cohorts, none of the three UCP2 polymorphisms were associated with GGT or
ALT levels. There was no evidence for interaction between the polymorphisms and alcohol intake on GGT and ALT levels.
In contrast, the association of WC and BMI with GGT levels varied by rs659366 genotype (PinteractionZ0.03 and 0.007,
respectively; adjusted for age, gender, high alcohol intake, diabetes, hypertension and serum lipid concentrations).icensed under a Creative Commons
.0 Unported License.
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173 :6 864Conclusion: In conclusion, our findings in 20 242 individuals suggest that UCP2 gene polymorphisms may cause liver
dysfunction through the interaction with body fat rather than alcohol intake.www.eje-online.orgEuropean Journal of
Endocrinology
(2015) 173, 863–872IntroductionUncoupling protein 2 (UCP2) is a heat-generating mito-
chondrial inner-membrane carrier protein that is widely
expressed in tissues including adipocytes (1) and liver
micro-lobules (2). Although liver is the major site of UCP2
expression in the rodent foetus, the levels decline soon
after birth (3). However, under pathologic conditions such
as during inflammation (4) or steatosis, it increases (5);
UCP2 gene expression has also been shown to occur in the
hepatocytes of both normal adult rodents and healthy
human adults, in the central area of the lobules (2). The
role of UCP2 in obesity and liver disease is substantiated by
the evidence that UCP2 enhanced fat accumulation in the
liver, increased insulin resistance (6) and stimulated
protective peripheral and central neural mechanisms in
acute ethanol intake (7).
Polymorphisms within the UCP2 gene have been
shown to be associated with various metabolic traits
such as obesity (8, 9) and type 2 diabetes (10, 11).
Although the effects of these polymorphisms on UCP2
function are still unclear, it could be hypothesised that the
loss-of-function polymorphisms are likely to contribute to
type 2 diabetes as a result of lower hepatic glucose uptake
(12). This is due to reduced glucose reabsorption in the
central areas of liver lobules, where this normally occurs
(13) – a suggestion supported by the report of reduced
type 2 diabetes risk with one UCP2 polymorphism (14).
There could also be an increase in the risk of metabolic
acidosis due to the switch of ammonia detoxification
from glutamine synthesis to ureogenesis (15). The gain-
of-function polymorphisms in the UCP2 gene could cause
damage of centrilobular cells due to repeated episodes of
undue hyperthermia, which is likely to occur during
ethanol ingestion but not in non-drinkers (16).
Based on the hypothesis that UCP2 gene polymorph-
isms can act as possible modulators of increases in liver
enzymes through either fat accumulation or alcohol
intake, we tested for the interaction effects between
tagging single-nucleotide polymorphisms (tagSNPs) in
the UCP2 gene and alcohol intake and obesity traits on
alanine aminotransferase (ALT) and gamma glutamyltransferase (GGT), commonly used indicators of liver
function, in a large meta-analysis of data sets from three
populations (total n up to 20 242).Subjects and methods
Study participants from three studies – namely, the
Northern Finland Birth Cohort 1966 (NFBC 1966; n up
to 4996), Netherlands Study of Depression and Anxiety
(NESDA; n up to 1883) and LifeLines Cohort Study (n up to
13 363) – were included in the meta-analysis.Data collection
NFBC 1966 was originally designed to study factors
affecting pre-term birth, low birth weight and subsequent
morbidity and mortality (17). Mothers living in the two
Northern-most provinces of Finland were invited to
participate if they had expected delivery dates during
1966. A total of 12 058 live births were included in the
study. At age 31, all individuals still living in the Helsinki
area or Northern Finland were asked to participate in a
detailed biological and medical examination (nZ6007) as
well as a questionnaire. The sample size available for the
present study was 5292 with data on genetic and
phenotypic information. Written informed consent was
obtained from all of the participants and the Ethics
Committee of the Faculty of Medicine at the University
of Oulu approved the study.
Netherlands Study of Depression and Anxiety " NESDA
is a multicentre study (18) designed to examine the long-
term course and consequences of depressive and anxiety
disorders (http://www.nesda.nl). NESDA included both
individuals with depressive and/or anxiety disorders and
controls without psychiatric conditions. Inclusion criteria
were age 18–65 years and self-reported western European
ancestry; exclusion criteria were not being fluent in Dutch
and having a primary diagnosis of another psychiatric
condition (psychotic disorder, obsessive compulsive
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173 :6 865disorder, bipolar disorder or severe substance use
disorder). The sample size available for the present study
was 1925 with data on genetic and phenotypic infor-
mation. Written informed consent was obtained from all
the participants and the study was approved centrally by
the Ethical Review Board of the VU University Medical
Center and subsequently by local review boards of each
participating centre.
LifeLines Cohort Study " LifeLines is a multidisciplinary
prospective population-based cohort study examining, in
a unique three-generation design, the health and health-
related behaviours of 167 729 persons living in the
northeast region of The Netherlands. It employs a broad
range of investigative procedures in assessing the biome-
dical, socio-demographic, behavioural, physical and
psychological factors that contribute to the health and
disease of the general population, with a special focus on
multimorbidity and complex genetics. The sample size
available for the present study was 13 363 with data on
genetic and phenotypic information. The LifeLines study
has been approved by the review board of the University
Medical Center, Groningen, and adheres to the principles
expressed in the Declaration of Helsinki. All study
participants provided written informed consent.Measurement of clinical parameters and variables
Northern Finland Birth Cohort 1966 " Anthropometric
measures, including height, weight and waist circumfer-
ence (WC), were measured without shoes and in under-
wear by a trained nurse. BMI was calculated as weight
(kg)/height (m)2. The usage of alcohol was assessed by
questionnaire (19). The alcohol variable was measured in
g/day, calculated by the product of the frequency of how
often alcoholic drinks are taken, which is converted to the
proportion of days when drinking per year, the number of
glasses taken when drinking and 12 (the average amount
of grams of alcohol in a glass). ALT and GGT levels were
measured by the Roche/Hitachi Modular Analyzer.
Netherlands Study of Depression and Anxiety " Indivi-
duals who used antidepressants (not serotonin-specific
reuptake inhibitors) were excluded from the analyses.
Height, weight and WC were measured during a medical
examination. BMI was calculated as weight (kg)/height
(m)2. Data on alcohol use were collected using the Alcohol
Use Disorder Identification Test questionnaire. The alco-
hol variable was measured in g/day, calculated by the
product of the frequency of how often alcoholic drinks aretaken, which is converted to the proportion of days when
drinking per year, the number of glasses taken when
drinking and 12 (the average amount of grams of alcohol
in a glass). Liver enzyme levels were determined with
Roche Diagnostic assays.
LifeLines Cohort Study " Height, weight and WC were
measured during the nurse visit without shoes and in light
clothing. BMI was calculated as weight (kg)/height (m)2.
The alcohol variable was measured in number of glasses
per month and subsequently converted to grams of
alcohol per day using an average of 10 g alcohol/glass
(10 g a day was based on the Dutch estimations of a glass
per day). GGT and ALT plasma levels were determined by
routine clinical chemistry at the UMCG (Groningen, The
Netherlands) using the Roche/Hitachi Modular System
(Roche).TagSNP selection
TagSNPs in the UCP2 gene were selected using genotype
data from the International HapMap collected in individ-
uals of Northern and Western European ancestry (CEU;
HapMap data release 24/phase II Nov 08, on NCBI B36
assembly, dbSNP b126). The Haploview Software V3.3
(http://www.broadinstitute.org/haploview/haploview-
downloads) was used to assess the linkage disequilibrium
structure between SNPs (20). Tagger Software (Cambridge,
MA, USA) was used to select tagSNPs with the ‘pairwise
tagging only’ option and an r2 threshold ofO0.8 (G10 kb
upstream and downstream of the genes). In the tagSNP
selection, we forced inclusion of the functional SNP
previously studied (rs659366, K866 G/A promoter poly-
morphism) before running Tagger. At the time of the
present study, we selected three tagSNPs – namely
rs2306819, rs599277 and rs659366 – representing all of
the common genetic variations within the UCP2 gene
according to the HapMap data release 24/phase II Nov 08,
on NCBI B36 assembly, dbSNP b126. However, we capture
only 75% of the UCP2 gene variations according to the
current HapMap data release 27/phases IICIII, Feb 09, on
NCBI B36 assembly, dbSNP b126.Genotyping
Northern Finland Birth Cohort 1966 " For NFBC,
genomic DNA was extracted from whole blood using
standard methods. All DNA samples for the Illumina
Infinium 370cnvDuo array were prepared for genotyping
by the Broad Institute Biological Sample Repository (BSP).www.eje-online.org
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173 :6 866All individuals in the study were genotyped with call rates
O95%. SNPs were excluded from analysis if the call rate in
the final sample was !95%, if the P value from a test of
Hardy–Weingberg equilibrium (HWE) was !0.0001, or if
the minor allele frequency (MAF) was!1%.
Netherlands Study of Depression and Anxiety " Indivi-
dual genotyping was conducted by Perlegen Sciences
(Mountain View, CA, USA) using a set of four proprietary,
high-density oligonucleotide arrays as part of the Genetic
Association Information Network (GAIN) (21). Samples
were excluded for failing quality control (QC) due to
uncertain linkage between genotype and phenotype
records, evidence of contamination, missing genotype
data, high genome-wide homozygosity (w75%), first- or
second-degree relationships or non-Caucasian ancestry.
SNPs were required not to have any of the following
features: gross mapping problem, greater than one
genotype disagreements in 40 duplicated samples, greater
than one Mendelian inheritance errors in complete
trio samples, MAF !0.01 or O0.05 missing genotypes.
A Hardy–Weinberg filter was not used. A total of 435 291
SNPs met these criteria and were included in the final
analysis data set.
LifeLines Cohort Study " Genotyping for Lifelines was
performed on the Illumina CytoSNP12 v2 chip. Samples
were excluded based on call rates below 0.95, gender
mismatch, duplicate discordance and genetic similarity.
Population stratification was assessed by principal
component analysis over the sample correlation matrix,
based on 16 842 independent SNPs. Samples were
excluded when for they diverged from the mean with at
least three S.D.s (Z-score O3) for the first five principal
components. SNPs were excluded with a MAF of !0.01,
call rate !0.95 or deviation from HWE (P!1!10K5).
Genome wide genotype imputation was performed using
Beagle v. 3.1.0, using the NCBI build 36 of phase II
HapMap CEU data (release 22) as a reference panel.Statistical analysis
All of the SNPs were coded additively and with the effect
allele as the minor allele. The metabolic measures GGT
and ALT were highly skewed and were therefore dichot-
omised as normal or high using the population-based
reference values (22). Individuals were considered to
have high levels of ALT if their ALT value was O50 or 38
for men and women respectively. For GGT, the cut-off
for high levels was 58 for men and 42 for women.www.eje-online.orgLogistic regression models were used to evaluate the
interaction between the polymorphisms and BMI, WC
and alcohol intake on the dichotomised GGT and ALT
levels. In all three cohorts, logistic regression models were
adjusted for age, gender, high alcohol intake (defined
as the top 10% of the distribution for each sex), obesity
(BMI !30 vs R30 kg/m2), diabetes, hypertension and
lipid medication or hyperlipidaemia. In the presence of
heterogeneity of effects between the studies, we used a
random-effects meta-analysis; otherwise, we tested using
fixed-effects inverse variance meta-analysis. All analyses
were carried out using STATA (College Station, TX, USA),
version 12. A P value of !0.05 was considered to be
statistically significant.Results
As shown in Table 1, in the NFBC 1966 cohort, men had
significantly higher BMI (P!0.001) and WC (P!0.001)
and a significantly greater proportion of high GGT levels
(P!0.001). No significant differences were observed
between men and women for proportions of alcohol
consumption (PZ0.96) and high ALT levels (PZ0.94).
Similar findings were observed in NESDA and LifeLines,
except for proportion of high ALT levels, which were
significantly higher in men in both cohorts.Main effects
The genotype and allele frequencies of the three UCP2
SNPs are presented in Table 2 and the three SNPs were in
HWE (PO0.05). None of the three polymorphisms showed
an association with ALT and GGT levels in in the meta-
analysis of the three cohorts (Table 3).Interaction of the UCP2 polymorphisms with alcohol
intake and obesity traits on ALT and GGT levels
Of the three UCP2 polymorphisms, only SNP rs2306819
showed evidence for an interaction with alcohol intake on
GGT levels in the NFBC 1966 (PinteractionZ0.02). This
interaction was, however, not observed in NESDA, Life-
Lines or in the meta-analysis of the three cohorts
(Pinteraction O0.53, for all interactions). None of the other
interactions with high alcohol intake on GGT levels were
significant in the meta-analysis of the three cohorts
(Pinteraction O0.54, for all; Table 4). There was also no
evidence for interaction between the SNPs and alcohol
intake on ALT levels in the meta-analysis (Pinteraction
O0.26, for all).
Table 1 Clinical and biochemical characteristics of the study participants. Values represented are meansGS.D.
Clinical and biochemical
parameters
NFBC 1966 NESDA LifeLines
Men (nZ2535) Women (nZ2757) Men (nZ622) Women (nZ1303) Men (nZ5579) Women (nZ7784)
Age (years) 31 31 43.9G12.0 40.9G12.7 49.0G11.7 48.5G11.3
BMI (kg/m2) 25.2G3.6 24.2G4.7 26.3G4.3 25.3G5.3 26.7G3.6 26.1G4.7
WC (cm) 88.9G9.9 78.9G12.1 96.3G13.2 85.4G13.7 96.6G10.5 88.5G12.2
Obese (%) 8.3 9.5 17.9 16.5 15.4 17.3
Alcohol (g/day) 13.9G20.6 4.9G8.2 17.5G22.1 9.2G13.2 13.9G12.8 4.1G6.8
GGT (U/l)a 20 (14, 32) 11 (8, 16) 26 (17.8, 39) 15 (11, 22) 27 (20, 39) 17 (13, 23)
High GGT levels (%) 8.6 2.7 12.8 5.8 10.4 6.26
ALT (U/l)a 6 (2.5, 10) 5.5 (2.5, 9) 26.3 (19, 37) 16.9 (13, 22) 26 (20, 35) 17 (13, 22)
High ALT levels (%) 8.6 8.7 11.3 5.3 8.77 4.12
aFor GGT and ALT levels, values presented are medians (interquartile range).
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173 :6 867In contrast, in the analyses on obesity-related traits in
the NFBC 1966, all of the three UCP2 polymorphisms
showed an interaction with BMI (Pinteraction !0.04) and
WC (Pinteraction !0.004) on GGT levels, while two
polymorphisms (rs599277 and rs659366) also suggested
an interaction with obesity (as a binary trait) on GGT
(Pinteraction!0.03) (Table 5). Themeta-analysis of the three
cohorts confirmed the interactions between the SNP
rs659366 andWC and BMI on GGT levels (WC, Pinteraction-
Z0.03 and BMI, PinteractionZ0.007), while for the other
two polymorphisms (rs599277 and rs2306819), evidence
for interaction was not consistent; the SNP rs2306819
showed an interaction with WC (PinteractionZ0.04) but not
BMI (PinteractionZ0.08) and obesity (PinteractionZ0.22), and
SNP rs599277 showed an interaction with BMI (Pinteraction-
Z0.01) and obesity (PinteractionZ0.03) but not WCTable 2 The genotype and allele frequencies of the three UCP2 g
UCP2
polymorphisms
NFBC 1966
Men Women Men
rs2306819
CC 1232 1329 276.1
CT 1051 1132 296.0
TT 236 272 49.6
MAF (%) 30 31 32
rs599277
GG 640 700 200.4
AG 1202 1332 317.4
AA 621 668 103.7
MAF (%) 50 49 42
rs659366
CC 944 1024 248.9
CT 1201 1309 295.0
TT 395 432 77.6
MAF (%) 39 39 36
MAF, minor allele frequency.
aImputed genotypes.(PinteractionZ0.09) (Table 5). None of the interactions
between the three SNPs with obesity traits on ALT levels
were statistically significant (data not shown).Discussion
The important finding of our study is that the effect of
UCP2 gene polymorphisms on liver function (as measured
by GGT and ALT levels) is likely to be modified by levels of
body fat rather than alcohol intake. Our meta-analysis in
20 242 individuals suggested that the functional UCP2
gene polymorphism, rs65966, interacts with both WC
(measure of central body fat distribution) and BMI
(measure of body fat levels) on its influence on GGT
levels. This finding is in line with the role of UCP2 in the
accumulation of fat in the hepatocytes (6), which is likelyene polymorphisms in the three cohorts stratified by gender.
NESDAa LifeLines
Women Men Women
1 584.61 2188 3056
2 569.78 2801 3862
2 148.17 590 866
33 36 36
1 396.30 1715 2415
2 638.30 2806 3827
7 267.48 1058 1542
45 44 44
9 514.22 2179 3022
3 616.22 2616 3610
5 171.85 784 1152
37 37 38
www.eje-online.org
Table 3 Association of the UCP2 gene polymorphisms with ALT and GGT levels.
Study cohorts
rs2306819 rs599277 rs659366
bGS.E.M. P value* bGS.E.M. P value* bGS.E.M. P value*
ALT levels
NFBC 1966 K0.03G0.09 0.74 K0.11G0.08 0.17 K0.09G0.08 0.30
NESDA 0.09G0.15 0.54 0.04G0.14 0.79 K0.19G0.15 0.19
LifeLines K0.03G0.06 0.65 0.01G0.05 0.80 0.03G0.05 0.62
Meta-analysis 0.05G0.68 0.68 0.04G0.63 0.63 0.04G0.57 0.57
GGT levels
NFBC 1966 K0.14G0.11 0.21 K0.002G0.09 0.98 0.04G0.10 0.67
NESDA 0.01G0.15 0.93 K0.10G0.14 0.46 K0.17G0.15 0.23
LifeLines 0.04G0.05 0.42 0.06G0.05 0.24 0.07G0.05 0.14
Meta-analysis 0.008G0.04 0.85 0.03G0.04 0.44 0.05G0.04 0.27
*P values adjusted for age, gender, high alcohol intake, obesity, diabetes, hypertension and lipid medication/hyperlipidaemia.
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173 :6 868to result in an elevation of GGT levels due to resultant liver
dysfunction.
Given the role of UCP2 in the control of energy
metabolism (23), polymorphisms in the UCP2 gene have
been examined for their associations with obesity and its
related traits. The three commonly studied polymorph-
isms in the UCP2 gene areK866G/A polymorphism in the
promoter region, the Ala55Val polymorphism in the exon
4 and the 45 bp insertion/deletion polymorphism in the
3 0-UTR. These polymorphisms have been shown to be
associated with various metabolic traits such as obesity
(24), body fat distribution (25), resting energy expenditure
(26), type 2 diabetes (10) and insulin resistance (9, 27) in
various populations from different ethnic backgrounds
(24). However, there were also studies that failed to show
an association between these polymorphisms and meta-
bolic traits (8, 28, 29). These inconsistencies could be
attributed to the small sample size, incomplete coverage of
the UCP2 gene variations or potential population-specific
influences on metabolic traits (29). Hence, in our study weTable 4 Interaction between UCP2 gene polymorphisms and high
Study cohorts rs2306819
b coefficientsGS.E.M. (P values*) for interaction on ALT levels
NFBC 1966 K0.14G0.27 (0.61)
NESDA 0.05G0.38 (0.89)
LifeLines 0.14G0.16 (0.37)
Meta-analysis 0.07G0.13 (0.59)
b coefficientsGS.E.M. (P values*) for interaction on GGT levels
NFBC 1966 0.58G0.25 (0.02)
NESDA K0.13G0.35 (0.70)
LifeLines K0.03G0.13 (0.79)
Meta-analysis 0.07G0.11 (0.53)
*P values adjusted for age, gender, obesity, diabetes, hypertension and lipids.
www.eje-online.orghave performed a meta-analysis of data from three large
European cohorts (n up to 20 242) and used the tagSNP
approach to capture all common genetic variations within
the UCP2 gene. Even though the study protocol used in
the three cohorts were different and the participants were
from different geographical regions and age groups, the
three cohorts were of European ethnicity and the analyses
were adjusted for age, gender, alcohol consumption,
obesity, diabetes, hypertension and lipid medication.
However, we cannot completely rule out the effects of
other diseases (such as mental health-related outcomes in
NESDA) on our analysis.
Independent of the associations with obesity and
diabetes, UCP2 has also been implicated in non-alcoholic
fatty liver disease (NAFLD) (30). UCP2 gene expression has
been shown to be increased in the liver of rats with NAFLD
(31); however, the real effect of UCP2 on NAFLD is
still unclear. Several mechanisms have been hypothesised
(6, 30), and the accumulating evidence supports the role of
mitochondrial dysfunction in NAFLD, in which UCP2alcohol intake on ALT and GGT levels.
rs599277 rs659366
0.16G0.23 (0.50) 0.11G0.24 (0.64)
0.35G0.37 (0.35) 0.25G0.39 (0.52)
0.16G0.15 (0.29) 0.13G0.15 (0.40)
0.18G0.12 (0.89) 0.14G0.12 (0.26)
0.39G0.23 (0.09) 0.42G0.23 (0.07)
K0.09G0.33 (0.77) K0.24G0.35 (0.49)
K0.005G0.12 (0.97) K0.06G0.12 (0.62)
0.06G0.09 (0.54) 0.02G0.10 (0.85)
Table 5 Interaction between UCP2 gene polymorphisms and obesity, BMI and WC on GGT levels.
Study cohorts rs2306819 rs599277 rs659366
b coefficientsGS.E.M. (P values*) for interaction between polymorphisms and obesity on GGT levels
NFBC 1966 0.49G0.27 (0.07) 0.55G0.26 (0.03) 0.63G0.28 (0.02)
NESDA 0.26G0.32 (0.41) 0.64G0.32 (0.04) 0.83G0.33 (0.01)
LifeLines 0.04G0.11 (0.71) 0.10G0.10 (0.33) 0.12G0.11 (0.27)
Meta-analysis 0.12G0.09 (0.22) 0.20G0.09 (0.03) 0.24G0.09 (0.01)
(PZ0.06 if using RE meta-analysis,
p-hetZ0.04)
b coefficientsGS.E.M. (P values*) for interaction between polymorphisms and BMI on GGT levels
NFBC 1966 0.04G0.02 (0.04) 0.05G0.02 (0.01) 0.05G0.02 (0.02)
NESDA 0.02G0.03 (0.40) 0.04G0.03 (0.10) 0.02G0.03 (0.46)
LifeLines 0.007G0.01 (0.47) 0.01G0.009 (0.22) 0.02G0.009 (0.07)
Meta-analysis 0.02G0.009 (0.08) 0.02G0.008 (0.01) 0.02G0.008 (0.007)
b coefficientsGS.E.M. (P values*) for interaction between polymorphisms and WC on GGT levels
NFBC 1966 0.02G0.008 (0.005) 0.03G0.008 (0.0003) 0.03G0.008 (0.001)
NESDA 0.001G0.01 (0.94) 0.009G0.01 (0.36) 0.01G0.01 (0.26)
LifeLines 0.004G0.00 (0.28) 0.005G0.004 (0.19) 0.007G0.004 (0.05)
Meta-analysis 0.007G0.003 (0.04) 0.009G0.003 (0.006)
(PZ0.09 with RE meta-analysis,
p-hetZ0.03)
0.01G0.006 (0.001)
(PZ0.03 with RE meta-analysis,
p-hetZ0.03)
RE, random-effects; p-het, P value for heterogeneity between the studies. *P values adjusted for age, gender, high alcohol intake, diabetes, hypertension
and lipids.
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173 :6 869plays a vital role through its uncoupling of oxidative
phosphorylation (32). Further to the role of UCP2 in
NAFLD, UCP2 also has shown to stimulate protective
peripheral and central neural mechanisms in acute
ethanol intake (7). Hence, we aimed to investigate the
hypothesis (2) that alcohol intake could have an adverse
effect on liver function in individuals with gain of
function polymorphisms of the UCP2 gene that is not
seen in non-drinkers. One of the reasons for alcohol intake
not being an effect modifier in the link between UCP2
polymorphisms and GGT/ALT levels in this large-scale
meta-analysis could be because of the fact that the effect of
drugs on the observed association was not excluded.
Even though the interaction between the UCP2 gene
polymorphism, rs659366, andWC and BMI on GGT levels
was not significant in all the cohorts, there was a
consistent interaction of rs659366 with WC and BMI on
GGT levels in the meta-analysis of the three cohorts.
Findings from previous studies (25, 33) have also
implicated the role of UCP2 gene polymorphism,
rs659366, in WC and body fat composition, and hence,
our results are suggestive of the role of body fat as a
possible effect modifier of the link between UCP2 and liver
dysfunction.
The interaction between UCP2 and WC was observed
only when examining GGT levels as an outcome.
Although both ALT and GGT levels have been used as
indicators of liver dysfunction, GGT levels have been
shown to be better than ALT as predictors of metabolictraits such as diabetes (34). Also, some studies have
demonstrated a stronger association between GGT and
diabetes than between ALT and diabetes (35, 36).
Furthermore, GGT levels have been considered to have
the potential to be included in algorithms for metabolic
syndrome, because the predictive value in the diagnosis of
metabolic syndrome is higher for GGT as compared to ALT
(37). Hence, it is possible that the GGT levels, rather than
ALT, might be a marker of a mechanism that is responsible
for interaction between the UCP2 polymorphism and
body fat in our study.
Previous studies have functionally characterized the
role of the UCP2 gene promoter polymorphismK866 G/A
(rs659366) in obesity and diabetes (38, 39). The WT G
allele of the polymorphism has been shown to be
associated with enhanced adipose tissue mRNA expression
in vivo, reduced transcriptional activity in vitro and
increased risk of obesity (39). Also, the same poly-
morphism has been shown to affect the preferential
binding of PAX6 (a pancreatic transcription factor
involved in pancreatic b-cell development and function)
to the UCP2 gene promoter (38). In line with the
functionality of this polymorphism, our finding raises
the question of whether this polymorphism interacts with
body fat in altering GGT levels through a pathway
independent of obesity and diabetes. Hence, mechanistic
studies are required to understand the role of this
functional polymorphism in relation to body fat and
liver function.www.eje-online.org
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173 :6 870In summary, our study, in up to 20 242 individuals,
shows evidence for an interaction between UCP2 gene
polymorphism, rs659366, and WC and BMI on GGT
levels, suggesting that UCP2 gene polymorphisms may
cause liver dysfunction through the interaction with body
fat rather than alcohol intake. Further large studies are
required to confirm this finding and should focus on
considering the effect of drugs when testing for the
interaction with alcohol intake.Declaration of interest
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